A Modified Peptide Redirects the Immune System to Prevent an MS-Like Disease in Mice

What the researchers found

Researchers created a modified version of a myelin peptide (PLP 139-151) by changing a single amino acid — swapping tryptophan for glutamine at position 144. This altered peptide ligand (APL) prevented experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, when the disease was induced with the original peptide.

The APL worked by redirecting the immune response. Instead of producing inflammatory Th1 cells that attack myelin, the APL generated T cells that were cross-reactive with the original peptide but produced anti-inflammatory cytokines (IL-4 and IL-10) characteristic of Th2 and Th0 responses. When T cell lines generated with the APL were transferred to other animals, they protected against EAE.

This demonstrates that a single amino acid change in an antigenic peptide can fundamentally shift how the immune system responds — from destructive autoimmunity to protective tolerance.

Why it matters

This study demonstrated a powerful concept: you can take the very peptide that triggers an autoimmune attack and subtly modify it to redirect the immune system toward a protective response instead. This 'immune deviation' approach became a foundational strategy in peptide immunotherapy research for multiple sclerosis and other autoimmune diseases, showing that precision at the single amino acid level can flip the immune switch from attack to tolerance.

The numbers in context

1 amino acid change (Trp→Gln at position 144) · Th2 shift (IL-4, IL-10 production) · Complete EAE prevention

How the study worked

Researchers synthesized an altered peptide ligand (APL) of PLP 139-151 with a single substitution at the primary T cell receptor contact point. They tested whether the APL could prevent EAE in mice when co-administered with the disease-inducing native peptide. They characterized the T cell response by measuring cytokine profiles (Th1 vs Th2) and performed adoptive transfer experiments where APL-generated T cells were transferred to naive mice to test for protective effects.

Who was studied

Female mice with experimental autoimmune encephalomyelitis (EAE)

What this study cannot tell us

This is an animal model study using EAE in mice, which does not perfectly replicate human multiple sclerosis. The immune system in mice is simpler than in humans, and APL approaches that work in mice have had mixed results in human trials. The study does not address long-term durability of protection or potential safety risks of immune deviation.

How to read the evidence

This is a well-designed animal study published in the high-impact journal Immunity, with clear mechanistic data including cytokine profiling and adoptive transfer confirmation. However, as a mouse study, it has inherent limitations in predicting human outcomes.

When this study was published

Published in 1995, this is a foundational study in the altered peptide ligand field. While the specific approach has been refined over three decades, the core concept of immune deviation through peptide modification remains influential in autoimmune therapy research.

The bigger picture

This 1995 study was a landmark in peptide immunotherapy, establishing that altered peptide ligands could induce 'immune deviation' — shifting destructive immune responses toward protective ones. While subsequent human trials of APLs for MS had mixed results (some causing disease flares), the concept of using modified peptides to retrain the immune system remains a cornerstone of autoimmune therapy research and has influenced vaccine design and tolerance induction strategies.

Questions still open

• Can this single amino acid substitution approach translate safely to human multiple sclerosis treatment?
• How long does the protective immune deviation last, and would repeated dosing be needed?
• Could similar altered peptide ligands work for other autoimmune diseases driven by specific T cell responses?

Common questions

Read the original research

An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis.

Immunity, 3(4), 397-405

Citation

Nicholson, L B; Greer, J M; Sobel, R A; Lees, M B; Kuchroo, V K. (1995). An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis.. Immunity, 3(4), 397-405.